-
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects.
Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH.
Obstet Gynecol 2011;117:1384-91. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Contribution of ductus venosus doppler in first-trimester screening for major cardiac defects.
Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH.
Fetal Diagn Ther 2011;29:127-34. -
Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications.
Maiz N, Nicolaides KH.
Fetal Diagn Ther 2010;28:65-71. -
Two and three-dimensional imaging of coarctation shelf in the human fetus.
Molina FS, Nicolaides KH, Carvalho JS.
Heart 2008;94:584. -
Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness.
Maiz N, Plasencia W, Dagklis T, Faros E, Nicolaides K.
Ultrasound Obstet Gynecol 2008;31:256-60. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Nuchal translucency and the risk of congenital heart disease.
Hyett J, Sonek J, Nicolaides KH.
Obstet Gynecol 2007;109:1455-6. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype.
Ghi T, Huggon IC, Zosmer N, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:610-4. -
Nuchal translucency as a marker of congenital heart disease.
Perdu M, Hyett JA, Sharland G, Snijders RS, Nicolaides KH.
Contracept Fertil Sex 1999;27:I-V. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
BMJ 1999;318:81-5. -
Cardiac expression of sarcoplasmic reticulum calcium ATPase in fetuses with trisomy 21 and trisomy 18 presenting with nuchal translucency.
von Kaisenberg CS, Huggon I, Hyett JA, Farzaneh F, Nicolaides KH.
Fetal Diagn Ther 1997:12:270-3. -
Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects.
Hyett JA, Perdu M, Sharland GK, Snijders RSM, Nicolaides KH.
Ultrasound Obstet Gynecol 1997;10:242-6. -
Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses.
Hyett J, Moscoso G, Nicolaides KH.
Am J Med Genet 1997;69:207-16. -
Case report: uniparental disomy 16 in association with congenital heart disease.
O'Riordan S, Greenough A, Moore GE, Bennett P, Nicolaides KH.
Prenat Diagn 1996;16:963-5. -
Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses.
Hyett JA, Brizot ML, Von-Kaisenberg CS, McKie AT, Farzaneh F, Nicolaides KH.
Obstet Gynecol 1996;87:506-10.